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Delayed Plasmodium falciparum parasite clearance has been associated with Single Nucle-
otide Polymorphisms (SNPs) in the kelch protein propeller domain (coded by pfk13 gene).
SNPs in the Plasmodium falciparum multidrug resistance gene 1 (pfmdr1) are associated
with multi-drug resistance including the combination artemether-lumefantrine. To our knowl-
edge, this is the first work providing information on the prevalence of k13-propeller and
pfmdr1 mutations from Sédhiou, a region in the south of Senegal.
Methods
147 dried blood spots on filter papers were collected from symptomatic patients attending a
hospital located in Bounkiling City, Sédhiou Region, Southern Senegal. All samples were
collected between 2015–2017 during the malaria transmission season. Specific regions of
the gene pfk13 and pfmdr1 were analyzed using PCR amplification and Sanger sequencing.
Results
The majority of parasites (92.9%) harboured the pfk13 wild type sequence and 6 samples
harboured synonymous changes. Regarding pfmdr1, wild-type alleles represented the
majority except at codon 184. Overall, prevalence of 86Y was 11.9%, 184F was 56.3% and
1246Y was 1.5%. The mutant allele 184F decreased from 73.7% in 2015 to 40.7% in 2017.
The prevalence of haplotype NFD decreased from 71.4% in 2015 to 20.8% in 2017.
Conclusions
This study provides the first description of pfk13 and pfmdr1 genes variations in Bounkiling,
a city in the Sédhiou Region of Senegal, contributing to closing the gap of information on
anti-malaria drug resistance molecular markers in southern Senegal.
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Introduction
Malaria caused by P. falciparum remains a public health problem with the majority of cases
and deaths occurring in sub-Saharan Africa [1]. In Senegal, incremental interventions have
significantly reduced malaria morbidity and mortality rates [2,3]. Nonetheless, in Senegal half
a million people in the country suffered from malaria during 2018 [1].
Prevalence of malaria in Senegal varies across regions, with extremely low prevalence in
northern (0.1%) and western (0.2%) regions, and higher prevalence (up to 5.9%) in the southern
region [2,3]. Following World Health Organization (WHO) recommendations, in 2006, the
Senegalese health authorities changed the first line antimalarial drug to fixed dose artemisinin
combination therapies (ACTs); artemether+lumefantrine (AL) and artesunate+amodiaquine
(ASAQ), as first and second lines of treatment for uncomplicated P. falciparum malaria [4].
Artemisinin resistance, as well as resistance to other antimalarial partner drugs are present in 5
countries of the Greater Mekong subregion (in Southeast Asia) [5–7] and although it has not
yet been irrefutably documented in Africa [1], some reports have emerged lately [8–10].
Genome-wide analysis of artemisinin resistance in P. falciparum has demonstrated that
mutations in the propeller domain of the gene encoding the Kelch 13 (K13) protein (pfk13) are
associated with resistant in vitro and in vivo phenotypes in Southeast Asia [6,11,12]. Nine non-
synonymous mutations have been validated (F446I, N458Y, M476I, Y493H, R5397T, I543T,
P553L, R561H and C580Y) in the Pfk13 gene as molecular markers, alongside with eleven can-
didate mutations [13]. In sub-Saharan Africa, increasing frequencies of nonsynonymous muta-
tions on the pfk13 gene have been reported throughout the continent [14–16] including in
Senegal [17,18] and the neighbouring The Gambia [19,20], Guinea-Bissau [21] and Mali [22].
The P. falciparum multidrug resistance transporter 1 (pfmdr1) gene encodes an ABC trans-
porter protein located in the digestive vacuole of the parasite [23]. Pfmdr1 polymorphisms at
codons N86Y, Y184F, S1034C, N1042D, and D1246Y have been associated with drug resis-
tance to several antimalarials [24–26]. Drug pressure (in vivo) due to ACT partner drugs has
resulted in directional selection of pfmdr1 variants: 86Y, Y184 and 1246Y for amodiaquine
(AMQ) and N86, 184F and D1246 for AL [24–27] The same tendency is also observed in vitro
and ex vivo susceptibility assays [28,29]. Interestingly, allelic replacement of pfmdr1 86Y was
able to increase parasite susceptibility to dihydroartemisinin (DHA) in vitro [30].
Ex vivo susceptibilities to ACT partner drugs, lumefantrine (LUM) and AMQ, have been
decreasing since 2008 in Senegal and neighboring The Gambia and Mali [19,20,31]. In The
Gambia, some isolates have shown declining sensitivity to DHA in in vitro assays [19]. Despite
sustained drug pressure (accessible through public and private health facilities) and a high bur-
den of malaria, few studies on P. falciparum molecular markers of drug resistance surveillance
are available from southern regions of Senegal [32]. Most of the studies of molecular marker
surveillance in Senegal have been performed in Dakar and Thiés [17,31,33–41] (Fig 1). Our
study provides information on pfk13 and pfmdr1 from Bounkiling, a city located in the Séd-
hiou region, in the South of Senegal (Fig 1).
Sédhiou has year-round malaria transmission that peaks during the rainy season (June
through October) with sustained but lower transmission the rest of the year. This region lies
between two malaria endemic countries: The Gambia (66 cases/1000 people at risk) and
Guinea-Bissau (123 cases/1000 people at risk) [1].
Materials and methods
Sample collection
In this study, we collected 147 samples (blood spots on Whatman filter paper) from P. falcipa-
rum infected patients with uncomplicated malaria, attending the health center in Bounkiling,
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Senegal. After laboratory confirmation of malaria infection by microscopy or rapid diagnostic
test, patients were asked to participate in the study. Written informed consent was obtained
from all patients before sample collection. The study was reviewed and approved by the Ethical
Committee of the Ministry of Health of Senegal (082 MSAS/DPRS/CNERS). Samples were col-
lected during the peak malaria transmission period (October to December) in 2015, 2016 and
2017.
Genotyping of pfmdr1 and pfk13 genes
P. falciparum mutations associated with resistance to ACT components were typed using PCR
amplification and Sanger sequencing. We evaluated specific regions of the genes pfk13 (codon
436 to 706) and pfmdr1 (codons 86, 184 and 1246). DNA from 147 blood spots was extracted
using Chelex method [42] and DNA was stored at -20˚C.
For pfk13 one fragment containing the main polymorphisms associated with delayed clear-
ance in Southeast Asia was amplified by nested PCR as described elsewhere [43] with modifi-
cations. Briefly, specific primers were developed for this purpose (forward—3’ GAAAGAAG
CAGAATTTTATGG5’; reverse—3’ GCTTGGCCCATCTTTATTAGTTCCC 5’, obtaining a
fragment of 856bp. A semi-nested PCR was performed in some samples using the inner for-
ward primer 3’ GTGTAGAATATTTAAATTCG 5’ obtaining a fragment of 788bp.
For pfmdr1, specific primers were designed for the amplification of the fragment of 452bp
containing codons 86 and 184 (forward—3’ GTATGTGCTGTATTATCAGGAGGA 5’;
reverse—3’ TTAATTTATGTTTGTGGTGTCATATG 5’) and for the amplification of the frag-
ment of 508bp containing codon 1246 (forward—3’ CTACAGCAATCGTTGGAGAA 5’
Fig 1. Map of Senegal showing the different regions and the sample collection site.
https://doi.org/10.1371/journal.pone.0249357.g001
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reverse—3’ GAGAATAGCTATAGCTAGAGC 5’). PCR conditions 94˚C 2 min; [94˚C 1 min,
56˚C 1 min, 72˚C 1 min] 10X; [94˚C 1 min, 50˚C 1 min, 72˚C 1 min] 30X; 72˚C 3 min. An ali-
quot of the PCR products was analyzed by electrophoresis on a 2% agarose gel stained with
GreenSafe Premium (Nzytech, Portugal) to confirm single band amplification. All PCR prod-
ucts were then purified using SureClean Plus (Bioline) before Sanger sequencing at Eurofins
Genomics (GATC services, Germany).
Data analysis
Sequences were analyzed using Multalin software (http://multalin.toulouse.inra.fr/multalin/
multalin.html; free online) using P. falciparum-3D7 strain as wild type genotype.
The prevalence of a particular mutant allele was calculated as the proportion of the specific
mutant samples among the total number of samples successfully analyzed for this mutation.




Among the 147 samples analyzed, twenty-one of them tested negative for P. falciparum by
PCR (6/39 in 2015, 6/65 in 2016 and 9/43 in 2017), hence removed from further analysis. Of
the remaining 126 blood samples, 7 had no slide available, so they were not considered for the
parasitemia evaluation that varied between 0.02–9.33% with a median value of 0.67%. Of the
126 subjects, 72 (57.14%) were men and 54 (42.86%) were women, and age varied between
3–70 years, with a median of 18 years. The majority 46.83% (n = 59) were adults (over 20
years), 40.48% (n = 51) were adolescents and 12.69% (n = 16) were children between the age of
3 and 10 years.
Molecular markers of anti-malarial drug resistance
All 126 samples (from day 0 before treatment), were successfully sequenced for pfk13, 120
were wild type (identical to the reference, 3D7 strain) and 6 carried synonymous mutations
(Table 1). One of the synonymous mutations, C469C was previously described in Senegal [17].
Table 1. Mutations in pfk13 and pfmdr1 genes.
Year (n) pfk13 pfmdr1
Allele prevalence (%) Haplotype (%)
Codon (�) N86 86Y Y184 184F D1246 1246Y
2015 (33) F583F (2) 90.9 9.1 26.3 73.7 100 0 NFD (71.4)
NYD (14.3)
YFD (14.3)
2016 (59) F491F (1) 90.2 9.8 42.0 58.0 100 0 NFD (54.5)
NYD (40.9)
YFD (4.5)
2017 (34) G545G (1) 82.1 17.9 59.3 40.7 96.0 4.0 NFD (20.8)
C469C (1) NYD (62.5)
A627A (1) YFD (16.7)
overall 6�/126 88.1 11.9 43.8 56.3 98.5 1.5
�number of samples with synonymous mutation.
https://doi.org/10.1371/journal.pone.0249357.t001
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None of the pfk13 variants associated with artemisinin resistance in Southeast Asia [13] were
observed in our study (Table 1).
A total of 101, 96 and 68 samples were successfully genotyped for pfmdr1 codons 86, 184,
and 1246, respectively. Mixed pfmdr1 alleles were not observed. Overall, wild-type alleles pre-
dominated (Fig 2), except for codon 184 where the mutant allele 184F occurred more fre-
quently (56.3%) than the wild-type allele Y184 (43.8%; Table 1). When analyzed separately
over time, the prevalence of the mutant allele 184F decreased from 73.7% in 2015 to 58.0% in
2016 and to 40.7% in 2017 (Table 1).
For pfmdr1, only three haplotypes were identified with the following overall prevalence:
NFD (45.0%), NYD (43.3%) and YFD (11.7%). No triple pfmdr1 mutants were found at codon
86, 184, or 1246 (YFY). When compared between years, the prevalence of the triple haplotype
NFD decreased significantly from 71.4% in 2015 to 54.5% in 2016 and 20.8% in 2017 (Fig 2).
Discussion
Considering the trends of artemisinin decreasing activity [5–7], treatment efficacy should be
monitored at regular intervals. Monitoring should be performed by directly measuring efficacy
in vivo, or indirectly, by molecular markers surveillance, which can reveal drug response
trends that inform on the possible therapeutic life-span of a given treatment [13]. In Senegal,
ACTs (AL, ASAQ and DHA-piperaquine; DHA-PPQ) remain highly effective for the treat-
ment of uncomplicated P. falciparum malaria. In the few reported cases of recrudescence after
ACT treatment, parasite samples did not carry mutations in the K13-propeller domain [32].
These observations seem to follow the regional tendency.
In Senegal, there are currently no systematic (nationwide) epidemiological studies on
molecular markers of drug resistance. Although a number of studies have been published in
Senegal reporting mutations in pfk13 [20,31,32,36–38,44], samples from those studies originate
mostly from Thies and Dakar regions (near and around the capital). In one exception, a recent
study reported pfk13 SNPs from Diourbel (east of Thiés) and Kedougou, in the southeast of
the country (Fig 1); [32]. Hence the importance of our study, which analyses samples from
Bounkiling City, in the Sédhiou region in the south of Senegal (Fig 1). Our analysis revealed
that all but 6 of the isolates carried wild type K13-propeller. This is in line with recent observa-
tions in Senegal, where most of the samples were also wild type for K13-propeller domain
[17,32,38]. None of the 5 identified SNPs in our samples occurred in more than two samples
(Table 1). Nevertheless one study including 207 isolates from Thiés and Dakar [17], identified
a total of 22 SNPs in pfk13 propeller domain (7 synonymous and 15 non-synonymous). In our
Fig 2. Temporal changes of prevalence at codons 86, 184 and 1246 of pfmdr1. Percentage (%) inserted in the
graphic bars represents the prevalence of the alleles and haplotypes in each year.
https://doi.org/10.1371/journal.pone.0249357.g002
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work, we have identified only 6 polymorphisms 5 synonymous and one non-synonymous
(Table 1). Most of these polymorphisms were limited to single isolates, suggesting that they are
likely transient polymorphisms part of naturally evolving parasite populations. The fact that
some of these polymorphisms tend to occur in the same positions, might indicate that certain
regions of the gene are more disposed to variations then others. Also, pfk13 artemisinin-resis-
tance associated alleles being selected in Africa, may not be the same as the ones selected in
Southeast Asia. The synonymous polymorphism C469C might be particularly relevant
because, in this position, two variant amino acids (C469F and C469Y) have been previously
associated with slow clearance of parasitemia, after ACT therapy [45,46]. Additionally, this
polymorphism was also previously reported in samples from Thiés and Dakar in Senegal [17]
and in Ghana [47,48]. In the two countries bordering Sedhiou, The Gambia to the north and
Guinea-Bissau to the south (Fig 1), wild type pfk13 is highly prevalent and SNPs associated
with artemisinin resistance in Southeast Asia, have not been identified [19–21]. Nevertheless,
monitoring the prevalence of these loci over time may help to infer which alleles are biologi-
cally relevant or selected under drug pressure.
The molecular marker pfmdr1 86Y (together with pfcrt, initially driven through the parasite
population by the previous widespread use of chloroquine) has been decreasing in many parts
of Africa. This declining prevalence is accelerated in countries using AL, consistent with the
expected direction of selection [49,50]. Here we report a high prevalence of wild type alleles
N86 and D1246, which follow the tendency reported from northern Senegal, namely from
Thiés and Dakar [19,20,28,33,35,44,51–54], the neighbouring The Gambia [19,20,54], and
other West Africa countries [16,55]. The pfmdr1 86Y is associated with a longer time to rein-
fection after AL treatment and a shorter time after ASAQ [49], reinforcing its informative
value as a molecular marker of antimalarial drug susceptibility.
For codon 184, our analysis of pfmdr1 revealed differences in the distribution of mutant
allele between years. The high prevalence of 184F in 2015 (73.7%) decreased over time to
40.7% in 2017 (Fig 2; Table 1). Declining of 184F prevalence was previously reported in para-
site samples collected between 2012 and 2014 in northern Senegal [20,31,51] and in The Gam-
bia [20]. This decrease, in Senegal, was correlated with a local and temporary change to ASAQ
as first the line of treatment [31]. Three pfmdr1 haplotypes were identified in our study: NFD,
NYD and YFD. The haplotype YYY was not identified; however, this was not surprising since
YYY is believed to be selected under the pressure of DHA-PPQ treatment from a genetic back-
ground 86Y and Y184 [56,57]. DHA-PPQ has not been widely used in Senegal, except to com-
pensate for antimalarial drug shortages in 2010 and 2011 [32]. Other studies have reported
absence or low prevalence of the allele 1246Y [35] or the haplotype YYY haplotype in Senegal
(northern regions) [31]. The two haplotypes NFD and NYD were the most frequent triple hap-
lotypes found in our samples, as was the case in other studies from northern Senegal [31,51] in
the neighbouring The Gambia [19,20] and generally in Africa [50]. These observations argue
in favor of lumefantrine selecting the triple haplotype N86F184D1246 (NFD) [28,31,35,58–60]
and that this selection might be sequential; first N86, second D1246 and the last 184F
[24,50,61,62]. A high prevalence of haplotype NFD was observed in 2015 (71.4%) samples,
however, a significant decrease was detected in 2017 (20%) driven by the decline of the mutant
allele 184F (Fig 2). This decrease could be explained by therapy policy change, and/or intense
migration of parasite populations to Bounkiling from other regions of Senegal or the neighbor-
ing The Gambia or Guinea-Bissau. Malaria therapy policy did not change in Bounkiling dur-
ing 2016 and 2017, which could cause decreased in AL pressure hence accounting for the
observed decrease in 184F frequency. Recently, a decreasing trend in frequency of the 184F
allele around the same period, was reported from the neighboring Guinea-Bissau [21,63].
Hence intense migration of parasite populations to Bounkiling from Guinea-Bissau, could
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account (at least in part) for the observed 184F decreasing frequency trend. To the best of our
knowledge, there is no published information on the prevalence of these markers between
2015 and 2017 (or since 2017) either from other regions in Senegal or from the neighboring
The Gambia. A higher number of samples analyzed with next generation sequencing, would
increase the robustness of our results. A national survey of molecular markers of drug resis-
tance would help to clarify these results and better inform National Public Health Authorities
on first-line treatment regimens to manage uncomplicated P. falciparum malaria.
Conclusions
All isolates carried wild type pfk13 gene, except for 6 samples that carried 5 different synony-
mous SNPs. Prevalence of haplotype NFD in pfmdr1 gene, decreased over time from 2015 to
2017. To our knowledge, this is the first work providing information on the prevalence of
k13-propeller and pfmdr1 mutations in Sédhiou, a region in the south of Senegal. We are con-
tributing to the surveillance of molecular markers of drug resistance in Africa.
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